All In Biotech

Drug Trial Radar · NCT00660907

Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients

A 52-Week International, Multi-centre, Randomised, Parallel-group, Double-blind, Active-controlled, Phase III Study With a 156-Week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin in Combination With Metformin Compared With Sulphonylurea in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Metformin Therapy Alone.

Last checked: Nov 20, 2026Latest source record: Mar 30, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,217 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,217

Actual

Start

Mar 2008

Primary completion

Dec 2009

Study completion Jan 2013

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Bristol-Myers Squibb
First posted
Apr 17, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being carried out to see if dapagliflozin as an addition to metformin is effective and safe in treating patients with type 2 diabetes when compared to glipizide (sulphonylurea) as an addition to metformin treatment.

Conditions

  • Type 2 Diabetes

Interventions

  • dapagliflozinDrug

    Tablet oral 2.5, 5, or 10 mg total daily dose once daily 208 weeks

  • glipizideDrug

    Capsule oral 5, 10, or 20 mg total daily dose once or split/twice daily 208 weeks

  • metformin hydrochlorideDrug

    Tablet oral 1500, 2000, or 2500 mg total daily dose split/twice daily 218 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adjusted Mean Change in HbA1c LevelsTime frame: Baseline to Week 52

Locations

76 sites in 10 countries. Site status is shown where the registry gives one.

  • Research Site

    Buenos Aires, Argentina

  • Research Site

    Caba, Argentina

  • Research Site

    Capital Federal, Argentina

  • Research Site

    Ciudad de Buenos Aires, Argentina

  • Research Site

    Córdoba, Argentina

  • Research Site

    Corrientes, Argentina

  • Research Site

    La Plata, Argentina

  • Research Site

    Rosario, Argentina

  • Research Site

    Santa Fe, Argentina

  • Research Site

    L'Aigle, France

  • Research Site

    Mûrs-Erigné, France

  • Research Site

    Nantes, France

  • Research Site

    Paris, France

  • Research Site

    Tours, France

  • Research Site

    Vannes, France

  • Research Site

    Bad Lauterberg im Harz, Germany

  • Research Site

    Berlin, Germany

  • Research Site

    Dresden, Germany

  • Research Site

    Essen, Germany

  • Research Site

    Frankfurt, Germany

  • Research Site

    Hamburg, Germany

  • Research Site

    Heilbronn, Germany

  • Research Site

    Ludwigshafen, Germany

  • Research Site

    Mainz, Germany

  • Research Site

    Pirna, Germany

  • Research Site

    Schmiedeberg, Germany

  • Research Site

    Wangen, Germany

  • Research Site

    Perugia, Italy

  • Research Site

    Pisa, Italy

  • Research Site

    Roma, Italy

  • Research Site

    Acapulco, Mexico

  • Research Site

    Guadalajara, Mexico

  • Research Site

    México, Mexico

  • Research Site

    Veracruz, Mexico

  • Research Site

    Deurne, Netherlands

  • Research Site

    Gorinchem, Netherlands

  • Research Site

    Groningen, Netherlands

  • Research Site

    Lichtenvoorde (gld), Netherlands

  • Research Site

    Losser, Netherlands

  • Research Site

    Poortvliet, Netherlands

Showing 40 of 76 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.